Key Takeaways
- Domestic formulation outperformed the market: Ipca grew 15% in Q4 vs IPM's 6%, driven by a metro-city focus that delivered 16% growth in the top 6 metros against the market's 8%.
- Unichem swung from a INR45 cr loss to INR100 cr EBITDA in one year, with low-hanging procurement and efficiency gains captured; the bigger portfolio-extension benefits are still to come.
- Standalone EBITDA margin jumped to 19.3% for FY24 from 16.2%, helped by lower material costs and a richer formulation mix, and management guided a further rise to 20.5–21% in FY25.
- The US build-out is finally moving from preparation to execution: the first shipment left the Silvassa plant, 6–7 launches are planned this year, and the Bayshore subsidiary is being wound down to route all US operations through Unichem.
- What to watch next quarter: Whether the 6–7 planned US product launches materialise on schedule, the pace of Unichem's margin climb toward the INR225 cr EBITDA target, and any sign that the acute segment recovery can lift domestic growth toward 14%.
Domestic Formulation: The Standout Engine
- Broad-based share gains: Ipca grew 15% in Q4 per IQVIA while IPM grew 6%, and for the full year it grew 13% against IPM's 8%. Market share rose to 2.04% from 1.88% a year ago, making Ipca the fastest-growing company among the top 25 players as of mid-March 2024.
- Acute and chronic both beat the market: In acute therapies, Ipca grew 11% against a market that grew just 3%; in chronic, Ipca grew 12% against 10% market growth.
- The metro bet is paying off: After increasing field force strength in metro cities over the last few years, Ipca achieved 16% growth in the top 6 metros versus market growth of 8%. Metros are now driving the business, though management declined to disclose the metro-wise sales split or dedicated field force numbers.
- Domestic outlook: Standalone domestic business is expected to grow around 12% in FY25, with management noting that if the acute segment revives and the overall market returns to 10–12% growth, Ipca's domestic growth could reach 14%.
Harish Kamath: "See, what was happening, any incremental raw material cost, we used to pass on. But unfortunately, the situation was not so in the last 2 financial years because of stocking and other situation. But hopefully, going forward, everything should get normalized."
Unichem Turnaround & Integration
- From loss to profit in one year: Unichem moved from minus INR45 crores EBITDA to INR100 crores EBITDA, driven by low-hanging fruit: material buying rationalisation, utility cost reductions, and production efficiency improvements.
- What has been captured vs what is pending: Procurement advantages from higher combined volumes, avoidance of duplicate costs, and operational efficiency gains at Unichem's API facilities have already contributed. The bigger benefits, sourcing Unichem's products from Ipca's APIs and extending Unichem's portfolio into Europe, Australia, New Zealand, Canada and South Africa, are work in progress and will take time because everything is regulated.
- API cost reduction is still ahead: Switching Unichem to Ipca's APIs requires stability studies, filings and approvals; those benefits have not yet started to flow into EBITDA.
- FY25 target: Unichem is expected to reach around INR225 crores EBITDA in the current year, on revenue of around INR1,700–2,000 crores, with 5–6 US formulation launches planned. Management expressed confidence that all acquisition-case targets will be achieved, "and better than that would be achieved."
Ajit Kumar Jain: "So I would say that we are confident in whatever we had talked around acquisition time and all. We are confident that all those things will be achieved. And better than that would be achieved, yes."
US Market: The Build-Out Begins
- First shipments have left: The Silvassa facility has started manufacturing for the US market; two formulations were shipped in the current month, with another two to three products under commercialisation. The Bayshore subsidiary is being wound down, and all US operations will now run through Unichem, with Ipca's products distributed via Unichem.
- Launch cadence: Around 6–7 products are expected to launch in the US this financial year from the approved portfolio. All 25–26 approved products should be in the market over three years; a few may not be viable now but most are, because they are sourced from Ipca's own APIs.
- ANDA filings are still distant: The pipeline is now being built, with R&D work underway, but stability studies will take 6–7 months followed by data compilation, so it will be some time before ANDA filings begin from Ipca's own plants. One Unichem facility was reinspected and cleared without any 483 observations.
Ajit Kumar Jain: "Overall, let's say, that as far as U.S. is concerned, we have not started so far filing the ANDAs from our plants because it will take -- we had -- nothing we had in the pipeline for U.S. And pipeline is now building. So people are working now in R&D and thereafter, buyback shares will be taken. Stability will take a lot of time, 6 to 7 months time and then data compilation."
Export Formulation: Generics Offset Branded Weakness
- Mixed performance: Export formulation grew around 9% in Q4, but full-year formulation growth was only around 7% (to INR1,775 cr from INR1,659 cr) because branded promotional markets like Russia and West Africa faced challenges, and the institutional generic business declined. Generic exports grew around 22% for the year to INR801 crores, partially offsetting those drags.
- FY25 outlook by segment: Export generics are expected to grow around 12%, while promotional markets will see lower growth due to currency depreciation in Russia and challenges in West Africa. The institutional business is expected to deliver around 14% growth.
Margins: Material Costs Drove the Step-Up
- Standalone EBITDA margin improved to 19.29% in FY24 from 16.22% in FY23, with Q4 at 18.5% versus 11.29% a year ago. Consolidated EBITDA margin rose to 16.72% from 15.3%.
- The drivers: Lower material costs (material cost-to-sales ratio improved to 32.08% from 35.58%), control over overhead expenses, and a higher contribution from the formulation business where value addition is greater. Price stability held for the majority of procurement.
- The Losartan factor: The major impact in the API business came from a single product, Losartan, where sale price and raw material price have now stabilised.
- Long-term ambition: Management aims to reach 24–25% margins over the next 6–7 years, with 100–150 bps improvement each year over the next 2–3 years. For FY25, standalone EBITDA margin is guided to 20.5–21% and consolidated to around 18%.
Harish Kamath: "Our aim is to reach ultimately to that level of around 24%, 25% over the next 6, 7 years."
API & Other Businesses
- API growth outlook: The API side is expected to grow around 7–8% in FY25. Raw material prices are stable, with management characterising the pricing environment as "more or less very steady" and noting that minor changes may happen but will not impact right now.
- Continuous manufacturing: Work on a continuous manufacturing facility for an intermediate (not for sartans) is progressing, but management cautioned it will be slow: "You can't expect miracle over there. Things are happening, but it is slow."
- R&D spend: Expected to remain in the range of 3.25–3.5% of sales.
- Capex: Consolidated capex is guided at around INR300–350 crores, with total capex around INR500 crores.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Standalone revenue growth | 10.5–11% | FY25 |
| Consolidated revenue growth | 14–14.25% | FY25 |
| Standalone EBITDA margin | Improve from 19.29% to 20.5–21% | FY25 |
| Consolidated EBITDA margin | Improve from 16.72% to ~18% | FY25 |
| Unichem EBITDA | Reach ~INR225 cr (from INR100 cr) | FY25 |
| US product launches | 6–7 products from approved portfolio | FY25 |
| All 25–26 approved US products in market | Commercialised across ~3 years | Over 3 years |
| Margin trajectory | 100–150 bps improvement per year | Next 2–3 years |
| Long-term margin target | 24–25% | Next 6–7 years |
| R&D spend | 3.25–3.5% of sales | FY25 |
| Consolidated capex | INR300–350 cr (total ~INR500 cr) | FY25 |
Key Metrics
| Metric | Q4 FY24 |
|---|---|
| Stand-alone revenue growth | ~10.5% to 11% guided for FY25 |
| Consolidated revenue growth | ~14% to 14.25% guided for FY25 |
| Stand-alone EBITDA margin | ~18.5%, up from 11.29% in Q4 FY23 |
| Consolidated EBITDA margin | ~14.98%, up from 11.29% in Q4 FY23 |
| Stand-alone EBITDA margin (full year) | ~19.29%, up from 16.22% in FY23 |
| Consolidated EBITDA margin (full year) | ~16.72%, up from 15.3% in FY23 |
| Material cost to sales ratio (stand-alone, full year) | ~32.08%, improved from 35.58% in FY23 |
| Domestic formulation growth (Q4) | ~13% |
| Domestic formulation growth (IQVIA, Q4) | 15%, vs IPM growth of ~6% |
| Acute segment growth (IQVIA, Q4) | ~11%, vs market growth of 3% |
| Chronic segment growth (IQVIA, Q4) | ~12%, vs market growth of ~10% |
| Overall market share (IQVIA) | 2.04%, up from 1.88% in March 2023 |
| Top 6 metros growth (IQVIA) | ~16%, vs market growth of ~8% |
| Export formulation growth (Q4) | ~9% |
| Generic export growth (full year) | ~22% to ~INR801 cr |
| R&D spend (Ipca + Unichem) | ~INR250 cr, ~3.25% to 3.5% of sales |
| U.S. product launches expected (FY25) | 6 to 7 products |
| Unichem EBITDA (FY24) | INR100 cr, up from minus INR45 cr in FY23 |
| Unichem EBITDA guidance (FY25) | ~INR225 cr |
| Consolidated capex guidance (FY25) | ~INR500 cr |
| U.S. facilities EBITDA drag | ~INR50 cr to INR60 cr |